Clinical Trials Browser

Phase 2 × Inflammation × 90 days × Clear all

Frailty, Inflammation

NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

Clinical Trials

ReFOCUS2

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease